European Companies Search Engine
Managing Director: Anton Karremann, Kristian Ruepp · No longer Managing Director: Katja Gogalla, Randi Mette Selnes · Address · Shareholder agreement · Name: FYB 202 Project GmbH · Corporate Purpose Hrb 27 Mar 2018 German Trade Register Announcements, Germany (26/03/2018)
Overview
Text
HRB 190578 B: Company/ Name formerly: Blitz B17-562 GmbH, Berlin, c/o Aristo Pharma GmbH,
Unnamed street ??, 13435 Berlin, Germany
. Company: FYB 202 Project GmbH; Seat/; Branch: Business address: c/o Aristo Pharma GmbH,
Unnamed street ??, 13435 Berlin, Germany
; Subject: Development of the biosimilar ustekinumab, as well as the related and related research, in order to finally obtain approval for a human medical treatment, which can and should then be commercialized. No longer Managing Director: 1. Gogalla, Katja; No longer Managing Director: 2. Selnes, Randi Mette; Managing Directors: 3rd Karremann, Anton, *??.??.????, Berlin; with the power to enter into legal transactions with himself or as a representative of third parties; Managing Director: 4. Dr. Ruepp, Kristian, *??.??.????, Berlin; with the power to enter into legal transactions with himself or a.s. a representative of third parties; Legal form: By resolution of the shareholders' meeting of December 21, 2017, the partnership agreement is amended to Sections 1 (company) and 4 (object).
This filing was translated from German to English. The filing refers to a past date, and does not necessarily reflect the current state. The latest known state is available on the following page: FYB202 Project GmbH, Planegg, Germany.